Gilead Sciences, Inc.
GILD.SW
Get informed when a big investor buys or sells
+ FollowMarket Cap$187.44B
Close$
Share Statistics
| Market cap | $187.44 Billion |
|---|---|
| Enterprise Value | $186.68 Billion |
| Dividend Yield | $2.58 (2.15%) |
| Earnings per Share | $6.84 |
| Beta | 0.34 |
| Outstanding Shares | 1,243,000,000 |
Return
| Return on Equity | -27.59% |
|---|---|
| Return on Assets | -6.56% |
| Return on Invested Capital | -4.38% |
Valuation & Multiples
| P/E Ratio | -58.14 |
|---|---|
| PEG | 9.15 |
| Price to Sales | 4.8 |
| Price to Book Ratio | 12.81 |
| Enterprise Value to Revenue | 6.13 |
| Enterprise Value to EBIT | -111.05 |
| Enterprise Value to Net Income | -58 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-5.86
Average shareholder expectationRevenue Estimate
$5.98 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$1.71
Average shareholder expectationRevenue Estimate
$6.28 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Gilead Sciences, Inc.
17,000 employees
CEO: Daniel O'Day Gilead Sciences, Inc. is a biopharmaceutical innovator dedicated to the research, development, and global commercialization of medicines that address significant unmet medical needs across the United States, Europe, and other internation...